Cargando…
Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers
Multidrug resistance (MDR) observed in tumors significantly hinders the efficacy of chemotherapy. Downregulation of efflux proteins, such as P-glycoprotein (P-gp), using small interfering RNA (siRNA) can be an effective way to minimize the resistance in tumors. In this study, monoclonal antibody 2C5...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324017/ https://www.ncbi.nlm.nih.gov/pubmed/35890364 http://dx.doi.org/10.3390/pharmaceutics14071470 |
_version_ | 1784756703852494848 |
---|---|
author | Yalamarty, Satya Siva Kishan Filipczak, Nina Li, Xiang Pathrikar, Tanvi Vinod Cotter, Colin Torchilin, Vladimir P. |
author_facet | Yalamarty, Satya Siva Kishan Filipczak, Nina Li, Xiang Pathrikar, Tanvi Vinod Cotter, Colin Torchilin, Vladimir P. |
author_sort | Yalamarty, Satya Siva Kishan |
collection | PubMed |
description | Multidrug resistance (MDR) observed in tumors significantly hinders the efficacy of chemotherapy. Downregulation of efflux proteins, such as P-glycoprotein (P-gp), using small interfering RNA (siRNA) can be an effective way to minimize the resistance in tumors. In this study, monoclonal antibody 2C5 (mAb 2C5)-PEG(7k)-DOPE conjugates were post-inserted into the mixed dendrimer micelles containing generation 4 (G4) polyamidoamine (PAMAM)-PEG(2k)-DOPE and PEG(5k)-DOPE. The inherent amphiphilic nature of DOPE conjugates causes the copolymers to self-assemble to form a micelle, which can encapsulate hydrophobic chemotherapeutic drugs in its core. The siRNA electrostatically binds to the cationic charges on the G4 PAMAM dendrimer. The tumor-specific mAb 2C5 on the surface of these nano-preparations resulted in improved tumor targeting. This active targeting to tumors can cause increase in the drug and siRNA accumulation at the tumor site, and thereby minimizing the off-target effects. The micelles were shown to have higher cellular association and effectiveness in vitro. The immunomicelle preparation was also tested for cytotoxicity in breast (MDA-MB-231) and ovarian (SKOV-3TR) MDR cancer cell lines. |
format | Online Article Text |
id | pubmed-9324017 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-93240172022-07-27 Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers Yalamarty, Satya Siva Kishan Filipczak, Nina Li, Xiang Pathrikar, Tanvi Vinod Cotter, Colin Torchilin, Vladimir P. Pharmaceutics Article Multidrug resistance (MDR) observed in tumors significantly hinders the efficacy of chemotherapy. Downregulation of efflux proteins, such as P-glycoprotein (P-gp), using small interfering RNA (siRNA) can be an effective way to minimize the resistance in tumors. In this study, monoclonal antibody 2C5 (mAb 2C5)-PEG(7k)-DOPE conjugates were post-inserted into the mixed dendrimer micelles containing generation 4 (G4) polyamidoamine (PAMAM)-PEG(2k)-DOPE and PEG(5k)-DOPE. The inherent amphiphilic nature of DOPE conjugates causes the copolymers to self-assemble to form a micelle, which can encapsulate hydrophobic chemotherapeutic drugs in its core. The siRNA electrostatically binds to the cationic charges on the G4 PAMAM dendrimer. The tumor-specific mAb 2C5 on the surface of these nano-preparations resulted in improved tumor targeting. This active targeting to tumors can cause increase in the drug and siRNA accumulation at the tumor site, and thereby minimizing the off-target effects. The micelles were shown to have higher cellular association and effectiveness in vitro. The immunomicelle preparation was also tested for cytotoxicity in breast (MDA-MB-231) and ovarian (SKOV-3TR) MDR cancer cell lines. MDPI 2022-07-15 /pmc/articles/PMC9324017/ /pubmed/35890364 http://dx.doi.org/10.3390/pharmaceutics14071470 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Yalamarty, Satya Siva Kishan Filipczak, Nina Li, Xiang Pathrikar, Tanvi Vinod Cotter, Colin Torchilin, Vladimir P. Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers |
title | Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers |
title_full | Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers |
title_fullStr | Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers |
title_full_unstemmed | Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers |
title_short | Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers |
title_sort | co-delivery of sirna and chemotherapeutic drug using 2c5 antibody-targeted dendrimer-based mixed micelles for multidrug resistant cancers |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9324017/ https://www.ncbi.nlm.nih.gov/pubmed/35890364 http://dx.doi.org/10.3390/pharmaceutics14071470 |
work_keys_str_mv | AT yalamartysatyasivakishan codeliveryofsirnaandchemotherapeuticdrugusing2c5antibodytargeteddendrimerbasedmixedmicellesformultidrugresistantcancers AT filipczaknina codeliveryofsirnaandchemotherapeuticdrugusing2c5antibodytargeteddendrimerbasedmixedmicellesformultidrugresistantcancers AT lixiang codeliveryofsirnaandchemotherapeuticdrugusing2c5antibodytargeteddendrimerbasedmixedmicellesformultidrugresistantcancers AT pathrikartanvivinod codeliveryofsirnaandchemotherapeuticdrugusing2c5antibodytargeteddendrimerbasedmixedmicellesformultidrugresistantcancers AT cottercolin codeliveryofsirnaandchemotherapeuticdrugusing2c5antibodytargeteddendrimerbasedmixedmicellesformultidrugresistantcancers AT torchilinvladimirp codeliveryofsirnaandchemotherapeuticdrugusing2c5antibodytargeteddendrimerbasedmixedmicellesformultidrugresistantcancers |